$MEND's AI tech to be used in Mitochondrial research Nurosene Health Inc. ( $MEND.C $MENNDF) is up 8.62% on the CSE after announcing that it was selected by Mitacs Inc, alongside The University of Toronto and other research groups, to conduct research into mitochondrial genetics in neuropsychiatric and neurodegenerative diseases.
$MEND was chosen because of positive results from earlier research completed at the UoT using its NetraAI artificial intelligence technology.
The CSO of $MEND, Dr. Joseph Geraci expressed that this research will enhance NutraAI by allowing it to fast-track the identification of novel and commercially viable drug candidates, and accelerate the build of its drug IP portfolio.
You can read more on this research and how it will impact $MEND here: https://ca.finance.yahoo.com/news/nurosene-announces-research-partnership-designed-130000105.html
Currently $MEND is trading at $0.63, MC is $20.929M